---
title: Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory
  acute graft-versus-host disease (REACH4)
date: '2024-07-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39046767/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240724182556&v=2.18.0.post9+e462414
source: Blood
description: In REACH4 (NCT03491215), a phase 1/2, open-label, single-arm, multicenter
  study, the pharmacokinetics (PK), efficacy, and safety of ruxolitinib were evaluated
  in treatment-naïve and steroid-refractory pediatric patients with grade II-IV acute
  graft-versus-host disease (aGVHD; n=45). Ruxolitinib dosing was based on age and
  targeted the exposure in adults receiving 10 mg twice daily; group 1 (≥12 to <18
  years) received 10 mg twice daily and preliminary starting doses for groups 2 (≥6
  to <12 ...
disable_comments: true
---
In REACH4 (NCT03491215), a phase 1/2, open-label, single-arm, multicenter study, the pharmacokinetics (PK), efficacy, and safety of ruxolitinib were evaluated in treatment-naïve and steroid-refractory pediatric patients with grade II-IV acute graft-versus-host disease (aGVHD; n=45). Ruxolitinib dosing was based on age and targeted the exposure in adults receiving 10 mg twice daily; group 1 (≥12 to <18 years) received 10 mg twice daily and preliminary starting doses for groups 2 (≥6 to <12 ...